Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202

It is uncertain whether HIV-1 antiretroviral exposure and clinical response varies between males and females or different race/ethnic groups. We describe ritonavir-enhanced atazanavir pharmacokinetics in relation to virological failure, safety and tolerability in treatment-naive individuals to inves...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of antimicrobial chemotherapy 2014-12, Vol.69 (12), p.3300-3310
Hauptverfasser: Venuto, Charles S, Mollan, Katie, Ma, Qing, Daar, Eric S, Sax, Paul E, Fischl, Margaret, Collier, Ann C, Smith, Kimberly Y, Tierney, Camlin, Morse, Gene D
Format: Artikel
Sprache:eng
Schlagworte:
Acquired immune deficiency syndrome
Adult
AIDS
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - adverse effects
Anti-HIV Agents - pharmacokinetics
Atazanavir Sulfate
Clinical trials
Female
Gender differences
HIV Infections - drug therapy
Human immunodeficiency virus 1
Humans
Kinetics
Male
Metabolic Clearance Rate
Middle Aged
Oligopeptides - administration & dosage
Oligopeptides - adverse effects
Oligopeptides - pharmacokinetics
Original Research
Pharmacology
Plasma - chemistry
Protease inhibitors
Pyridines - administration & dosage
Pyridines - adverse effects
Pyridines - pharmacokinetics
Ritonavir - administration & dosage
Ritonavir - adverse effects
Sex Characteristics
Time Factors
Treatment Failure
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:It is uncertain whether HIV-1 antiretroviral exposure and clinical response varies between males and females or different race/ethnic groups. We describe ritonavir-enhanced atazanavir pharmacokinetics in relation to virological failure, safety and tolerability in treatment-naive individuals to investigate potential differences. Plasma samples were collected from participants in AIDS Clinical Trials Group Study A5202 for measurement of antiretroviral concentrations. Individual estimates of apparent oral clearance of atazanavir (L/h) were calculated from a one-compartment model and divided into tertiles as slow (
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dku303